USO 25175
C6461006: AN INTERVENTIONAL PHASE 1b/2, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, ANTITUMOR ACTIVITY, AND PHARMACOKINETICS OF PF08634404 MONOTHERAPY OR IN COMBINATION WITH ENFORTUMAB VEDOTIN IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER
Disease Types: Genitourinary Cancer Research
Eligibility Requirements:
• Histologically documented unresectable locally
advanced or metastatic urothelial cancer
• Cohort A: Previously treated (≤3 LOT) disease
• Prior platinum-containing therapy is allowed
• Cohort B: Previously untreated disease
• Subjects must have sufficient tumor tissue available
• Measurable disease based on RECIST 1.1
• Subjects with known active CNS lesions, including
leptomeningeal metastasis, brainstem, meningeal, or
spinal cord metastases or compression are excluded
For more details on this trial CLICK HERE .
Available at: